Compare HCA Health Inc (HCA) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs MasTec Inc — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while MasTec Inc trades at $212.65 (market cap $17.40B). The key difference: HCA Health Inc is far larger — about 5.5× MasTec Inc's market cap, and HCA Health Inc pays a 0.7% dividend while MasTec Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and MasTec Inc for 23 Days on average.
| HCA | MTZ | |
|---|---|---|
Market Cap | $96.35B | $17.40B |
Volume | 1,079,453 | 1,415,821 |
Sector | Health | Industrials |
52-Week High | $545.13 | $437.51 |
52-Week Low | $361.32 | $190.08 |
Typical Hold Time | 76 Days | 23 Days |
Enterprise Value | $146.88B | $20.32B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $445.01, up 1.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.60 billion in 2025, with a net income margin of 8.77%. The stock is supported by a consensus analyst price target of $461.12 and a 63% buy rating. Recent news includes an upcoming Q3 2026 earnings call and completion of the College of Health Care Professions acquisition, highlighting growth initiatives amid ongoing legal investigations.
Outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and regulatory scrutiny. The stock offers value with a P/E of 14.92 and upside to the price target, though high debt levels and legal overhangs warrant caution for investors seeking stable healthcare exposure.
MasTec (MTZ) trades at $216.66, down 3.0% on the day, amid bearish technical signals despite strong analyst support. The stock shows mixed earnings performance with recent Q2 2026 EPS missing expectations, but maintains robust revenue growth projections and a record $21.4B backlog. Current valuation metrics include a P/E of 34.5 and P/S of 1.06, while profitability metrics show a 3.07% net income margin and 15.39% ROE.
The investment outlook remains positive based on strong analyst consensus (88.9% buy ratings) and a $408.58 price target, representing significant upside potential. Key opportunities include infrastructure investment cycles and AI-driven data center demand, while risks include premium valuation, weak cash flow trends, and communications segment softness. The stock's current price near support levels offers potential entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
